✦ LIBER ✦

Butaperazine pharmacokinetics in tardive dyskinesia

✍ Scribed by Dr. Marion E. Wolf; Javaid I. Javaid; Aron D. Mosnaim; John M. Davis

Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 204 KB
Volume: 6
Category: Article
ISSN: 0142-2782
DOI: 10.1002/bdd.2510060213

No coin nor oath required. For personal study only.

✦ Synopsis

failed to show any significant differences in the steady-state serum levels of thioridazine or its metabolites between TD and non-TD schizophrenic subjects.

📜 SIMILAR VOLUMES

Tardive dyskinesias in the elderly

✍ G. Fabbrini; P. Barbanti; C. Aurilia 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Vitamin E Treatment in Tardive Dyskinesi

Vitamin E Treatment in Tardive Dyskinesia

✍ P. N. DANNON; E. LEPKIFKER; I. IANCU; R. ZIV; N. HORESH; M. KOTLER 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Sixteen patients with tardive dyskinesia were treated with vitamin E in an open trial of on±o±on design. Abnormal involuntary movement scale (AIMS) ratings were performed in every phase of the study. The patients exhibited a signi®cant reduction in their mean AIMS score during vitamin E treatment. T

APOE2 allele increased in tardive dyskin

APOE2 allele increased in tardive dyskinesia

✍ Jonathan Halford; Gandis Mazeika; Susan Slifer; Marcy Speer; Ann M. Saunders; Wa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

## Abstract Ninety‐seven inpatients with tardive dyskinesia (average AIMS score = 13), the majority of whom were schizophrenic, were studied. Forty patients were Caucasian, and 57 were African–American. The APOE genotypes of these patients were compared to previously published genotypes of controls

Tardive dyskinesia model in the common m

Tardive dyskinesia model in the common marmoset

✍ Rebecka Klintenberg; Lars Gunne; Per E. Andrén 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

## Abstract Thirteen adult common marmosets (__Callithrix jacchus__) were given once‐monthly injections of haloperidol decanoate (5–15 mg/kg i.m.) for one year. Thereafter, drug‐free and treatment periods alternated at 3‐month intervals. After 2.5 to 14 months, 12 monkeys showed symptoms of tardive

Metoclopramide-induced tardive dyskinesi

Metoclopramide-induced tardive dyskinesia in an infant

✍ Nicte I. Mejia; Joseph Jankovic 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB 👁 1 views

## Abstract We describe a 1‐year‐old girl who developed orofaciolingual stereotypy at age 2 months after a 17‐day treatment with metoclopramide for gastroesophageal reflux. The stereotypy, documented by sequential videos, persisted for at least 9 months after the drug was discontinued. This patient

VARIABLES ASSOCIATED WITH TARDIVE DYSKIN

VARIABLES ASSOCIATED WITH TARDIVE DYSKINESIA IN GEROPSYCHIATRIC OUTPATIENTS

✍ VICTOR A. MOLINARI; JANE MARMION; MARK KUNIK; RICHARD SOFINOWSKI 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 475 KB 👁 1 views

Age, sex, race, cognitive impairment, level of depression, psychiatric diagnosis and length of time receiving neuroleptic medication have been proposed as risk factors for the development of tardive dyskinesia (TD) in the elderly. The charts of 186 patients were reviewed to collect demographic, diag